The global antiepileptic drugs (AED) market size was estimated to be USD 16.43 billion in 2023 and is expected to reach at USD 30.04 billion by 2034 with a CAGR of 5.64% during the forecast period 2024-2034. The efficacy of antiepileptic drugs (AEDs) in managing seizures is on the rise, growing prevalence of epilepsy, increased demand for various treatment options, heightened emphasis on introducing new medications, a surge in clinical trial procedures, increase in regulatory approvals, enhanced awareness regarding the disease & advanced therapeutic options, growing geriatric population, rising advancements in early diagnosis techniques, increase in the innovation of antiepileptic drug (AED) development, and surge in regulatory approval of antiepileptic drug are some of the key factors boosting the market growth.
Surge in regulatory approval of antiepileptic drug is predicted to boost the market growth during the forecast period. Antiepileptic drugs (AEDs), often referred to as anticonvulsants or antiseizure medications, are regularly employed for the symptomatic management of epileptic seizures. These seizures manifest as recurrent episodes, originating from erroneous signals transmitted by nerve cells to the brain. Additionally, antiepileptic drugs serve as mood stabilizers and find application in treating bipolar disorders and neuropathic pain. For instance, in March 2022, Ztalmy (ganaxolone) has received approval from the U.S. Food and Drug Administration (FDA) for treating seizures linked to cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two years and above.
By drug generation, second-generation was the highest revenue-grossing segment in the global antiepileptic drugs (AED) market in 2023 owing to the rising benefits of drugs such as Lyrica, Keppra, Banzel, and others. The most popular medication for treating epilepsy has been Lyrica. It has demonstrated the ability to reduce seizure frequency and calm brain impulses. Additionally, first generation is predicted to grow at fastest CAGR during the forecast period owing to the presence of highly effective drugs and surge in collaborations within market players. For instance, in January 2022, Ovid Therapeutics Inc. has revealed its exclusive licensing agreement with AstraZeneca, encompassing a collection of early-stage small molecules aimed at the KCC2 transporter. This includes the primary candidate, OV350. The company aims to enhance and expedite the development of these activators for the KCC2 transporter, focusing on their application in epilepsies and potentially other neuropathic conditions.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global antiepileptic drugs (AED) market in 2023 owing to the rise of hospital pharmacies specializing in neurology and patients' inclination towards hospitals, drawn by their well-equipped advanced infrastructure & sufficient amenities, increasing count of hospitals, favorable reimbursement policies offered by these establishments, and growing mergers & acquisitions among market players. For instance, in February 2022, The procurement of Kv7 channel activators from Channel Biosciences, LLC has been concluded by Biohaven Pharmaceutical Holding Company Ltd. These activators are intended for specific indications, including epilepsy, pain disorders, and affective disorders. Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to a growing trend in these facilities to adopt epilepsy drugs, and the ready availability of these medications in easily accessible pharmacies benefits the patients.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in the rates of diagnosis & treatment for neurological conditions, favorable reimbursement policies for epilepsy drugs, an increase in research & development investments, a growing awareness among patients about new treatment options, the accessibility of advanced drugs, surge in regulatory approval of innovative drugs. For instance, in March 2022, The U.S. Food and Drug Administration (FDA) has approved ZTALMY® (ganaxolone) oral suspension to treat seizures associated with cyclin-dependent kinase-like 5 deficiency condition (CDD), according to a statement released by Marinus Pharmaceuticals, Inc. This rare genetic epilepsy condition is treated with ZTALMY in patients aged two years and older. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the upswing in the number of drugs obtaining regulatory approvals, an expansion of healthcare infrastructure, an increase in the prevalence of epilepsy disorders, and rising focus on the formulation of novel drugs. For instance, in august 2022, Eisai Co., Ltd. has officially submitted a supplementary new drug application in Japan for its internally developed antiepileptic drug (AED) Fycompa (perampanel). This application is made with the aim of obtaining approval for an injection formulation, introducing a new route of administration.
Surge in regulatory approval of antiepileptic drug is predicted to boost the market growth during the forecast period. Antiepileptic drugs (AEDs), often referred to as anticonvulsants or antiseizure medications, are regularly employed for the symptomatic management of epileptic seizures. These seizures manifest as recurrent episodes, originating from erroneous signals transmitted by nerve cells to the brain. Additionally, antiepileptic drugs serve as mood stabilizers and find application in treating bipolar disorders and neuropathic pain. For instance, in March 2022, Ztalmy (ganaxolone) has received approval from the U.S. Food and Drug Administration (FDA) for treating seizures linked to cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two years and above.
By drug generation, second-generation was the highest revenue-grossing segment in the global antiepileptic drugs (AED) market in 2023 owing to the rising benefits of drugs such as Lyrica, Keppra, Banzel, and others. The most popular medication for treating epilepsy has been Lyrica. It has demonstrated the ability to reduce seizure frequency and calm brain impulses. Additionally, first generation is predicted to grow at fastest CAGR during the forecast period owing to the presence of highly effective drugs and surge in collaborations within market players. For instance, in January 2022, Ovid Therapeutics Inc. has revealed its exclusive licensing agreement with AstraZeneca, encompassing a collection of early-stage small molecules aimed at the KCC2 transporter. This includes the primary candidate, OV350. The company aims to enhance and expedite the development of these activators for the KCC2 transporter, focusing on their application in epilepsies and potentially other neuropathic conditions.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global antiepileptic drugs (AED) market in 2023 owing to the rise of hospital pharmacies specializing in neurology and patients' inclination towards hospitals, drawn by their well-equipped advanced infrastructure & sufficient amenities, increasing count of hospitals, favorable reimbursement policies offered by these establishments, and growing mergers & acquisitions among market players. For instance, in February 2022, The procurement of Kv7 channel activators from Channel Biosciences, LLC has been concluded by Biohaven Pharmaceutical Holding Company Ltd. These activators are intended for specific indications, including epilepsy, pain disorders, and affective disorders. Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to a growing trend in these facilities to adopt epilepsy drugs, and the ready availability of these medications in easily accessible pharmacies benefits the patients.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in the rates of diagnosis & treatment for neurological conditions, favorable reimbursement policies for epilepsy drugs, an increase in research & development investments, a growing awareness among patients about new treatment options, the accessibility of advanced drugs, surge in regulatory approval of innovative drugs. For instance, in March 2022, The U.S. Food and Drug Administration (FDA) has approved ZTALMY® (ganaxolone) oral suspension to treat seizures associated with cyclin-dependent kinase-like 5 deficiency condition (CDD), according to a statement released by Marinus Pharmaceuticals, Inc. This rare genetic epilepsy condition is treated with ZTALMY in patients aged two years and older. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the upswing in the number of drugs obtaining regulatory approvals, an expansion of healthcare infrastructure, an increase in the prevalence of epilepsy disorders, and rising focus on the formulation of novel drugs. For instance, in august 2022, Eisai Co., Ltd. has officially submitted a supplementary new drug application in Japan for its internally developed antiepileptic drug (AED) Fycompa (perampanel). This application is made with the aim of obtaining approval for an injection formulation, introducing a new route of administration.
Segmentation: Antiepileptic Drugs (AED) Market Report 2023 - 2034
Antiepileptic Drugs (AED) Market Analysis & Forecast by Drug Generation 2023 - 2034 (Revenue USD Bn)
- Third Generation
- Second Generation
- First Generation
Antiepileptic Drugs (AED) Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Antiepileptic Drugs (AED) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Antiepileptic Drugs (AED) Market: Drug Generation Estimates & Trend Analysis
8. Antiepileptic Drugs (AED) Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Antiepileptic Drugs (AED) Market
11. Europe Global Antiepileptic Drugs (AED) Market
12. Asia Pacific Global Antiepileptic Drugs (AED) Market
13. Latin America Global Antiepileptic Drugs (AED) Market
14. MEA Global Antiepileptic Drugs (AED) Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Biohaven Pharmaceutical Holding Company Ltd
- Sunovion Pharmaceuticals Inc.
- Jazz Pharmaceuticals Inc.
- Ovid Therapeutics Inc.
- H. Lundbeck A/S
- Eisai Co. Ltd.
- Pfizer Inc.
- UCB S.A.
- GSK plc.
- Sanofi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 16.43 Billion |
| Forecasted Market Value ( USD | $ 30.04 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
